Welcome to our dedicated page for RenovoRx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.
RenovoRx, Inc. (RNXT) is a medical device and biopharmaceutical company based in Silicon Valley, California. The company focuses on developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents to specific locations in the peripheral vascular system. With FDA clearance for their flagship product, RenovoCath™ RC120, RenovoRx is introducing this cutting-edge technology to the clinical market.
RenovoRx's proprietary platform, Trans-Arterial Micro-Perfusion (TAMP), aims to revolutionize cancer treatment by ensuring precise therapeutic delivery directly to the tumor site. This targeted approach is designed to reduce the toxicities commonly associated with systemic intravenous therapy, potentially improving therapeutic outcomes for cancer patients.
The company is driven by a highly motivated team with extensive experience in the medical field and supported by a robust medical advisory board and a distinguished board of directors. RenovoRx's commitment to innovation and patient care has positioned it as a leader in the area of targeted therapeutic delivery.
For more information or inquiries, please contact RenovoRx at info@renovorx.com.
RenovoRx, Inc. (Nasdaq: RNXT) reported its financial results for Q2 2022, revealing cash and cash equivalents of $10.8 million. R&D expenses rose to $1.4 million from $0.5 million year-over-year, while G&A expenses increased to $1.2 million from $0.3 million. The company reported a net loss of $2.6 million, up from $1.3 million in the previous year. Key developments include an upcoming interim analysis of the Phase 3 TIGeR-PaC clinical trial for pancreatic cancer and a new Phase 2/3 trial protocol submission. RenovoRx is advancing its proprietary RenovoTAMP therapy platform.
RenovoRx, Inc. (Nasdaq: RNXT) has appointed James Ahlers as Chief Financial Officer (CFO) effective July 15, 2022, replacing Christopher J. Lehman. Ahlers brings over 25 years of experience in life sciences finance, having managed capital-raising efforts exceeding $2 billion. Additionally, Ronald B. Kocak joins as Vice President and Controller, previously serving as interim controller. The leadership change aims to support the company’s focus on expanding its clinical pipeline and enhancing operations.
RenovoRx has announced the launch of a new video series titled 'The RenovoRx Story,' focusing on its innovative RenovoTAMP™ therapy platform for treating difficult cancers. The series introduces the leadership team and provides insights into their Phase 3 TIGeR-PaC clinical trial for locally advanced pancreatic cancer. CEO Shaun Bagai emphasized the potential benefits of localized treatment over traditional systemic chemotherapy. The trial aims to improve survival rates and quality of life for patients. Additional video segments will be released soon.
RenovoRx, Inc. (NASDAQ: RNXT) will host a webinar on June 21 at 8:00 AM ET, discussing its RenovoTAMP™ therapy platform for pancreatic cancer treatment. Featured speakers include Dr. Michael Pishvaian from Johns Hopkins Kimmel Cancer Center and CEO Shaun R. Bagai. Dr. Pishvaian will explore existing treatment options and the innovative approach of the TIGeR-PaC trial that localizes chemotherapy delivery to tumors. The event will include a Q&A session, with a recording available on RenovoRx's website post-event. RenovoRx focuses on enhancing local tumor treatment with its proprietary technology.
RenovoRx, Inc. (Nasdaq: RNXT) will present at the Gateway to Translation Webinar Series hosted by the University of Cambridge's Academy of Therapeutic Sciences on June 8, 2022. Dr. Ramtin Agah, CMO and Co-Founder, will discuss the RenovoTAMP™ therapy platform designed for pancreatic cancer treatment. This innovative approach aims to improve patient survival and reduce chemotherapy side effects. A recording will be available on the RenovoRx website. The company's lead candidate, RenovoGem™, is in a Phase 3 trial for locally advanced pancreatic cancer.
RenovoRx (RNXT) announced it will present preclinical research on its Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy for cholangiocarcinoma at the GEST 2022 in New York City. The study showed that intra-arterial delivery significantly penetrated bile duct tissue compared to gallbladder delivery. RenovoRx plans to launch a Phase 2/3 study in cholangiocarcinoma in the latter half of 2022 and has received Orphan Drug Designation for this indication. The findings aim to offer a localized chemotherapy option, enhancing treatment efficacy and potentially improving survival rates.
RenovoRx, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami Beach, Florida. CEO Shaun Bagai is set to present on May 24 at 7:00 a.m. ET. The company specializes in localized treatments for cancer using its proprietary RenovoTAMP therapy platform. RenovoRx's lead product, RenovoGem, aims to treat locally advanced pancreatic cancer and is currently in Phase 3 trials. The event will also offer one-on-one meetings with investors.
RenovoRx (NASDAQ: RNXT) reported financial results for Q1 2022, highlighting significant progress in cancer treatment. The company has $13.1 million in cash, but reported a net loss of $3.0 million, up from $1.1 million the previous year. Research and development costs rose to $1.3 million due to the Phase 3 trial expenses for RenovoGem™, aimed at treating pancreas cancer. The FDA previously granted Orphan Drug Designation for this and other indications, underscoring the potential for improved patient outcomes.
RenovoRx, a biopharmaceutical company focused on targeted cancer therapies, announces its participation as a Silver Sponsor for the PurpleStride Silicon Valley event on April 30, aimed at combating pancreatic cancer. The event will resume in-person fundraising after two years of virtual events. Pancreatic cancer remains a critical health issue, with a five-year survival rate of just 11% and 62,000 diagnoses expected in 2022. RenovoRx aims to improve outcomes through its RenovoTAMP therapy platform and is advancing its lead product, RenovoGem, in clinical trials.
RenovoRx, Inc. (NASDAQ: RNXT) reported financial results for the year ended December 31, 2021. The company closed its IPO and successfully listed on NASDAQ. Despite the pandemic, it achieved about 50% enrollment in its Phase 3 clinical trial for locally advanced pancreatic cancer. Financially, cash equivalents stood at $15.2 million, with a net loss of $6.3 million, increasing from $3.8 million in 2020. Operational highlights included new patent issuance and 510(k) clearance for its RenovoCath delivery system.
FAQ
What is the current stock price of RenovoRx (RNXT)?
What is the market cap of RenovoRx (RNXT)?
What does RenovoRx, Inc. specialize in?
What is the RenovoCath™ RC120?
What is the Trans-Arterial Micro-Perfusion (TAMP) platform?
Where is RenovoRx headquartered?
Who backs RenovoRx's initiatives?
What is the primary goal of RenovoRx's therapies?
How can I contact RenovoRx for more information?
What makes RenovoRx's technology unique?
Is RenovoRx currently in clinical stages?
What recent achievements has RenovoRx made?
